The current study evaluated the predictive performance of AFP, PIVKA-II, and multiple prognostic models for HCC recurrence (RETREAT, MoRAL, SNAPP, and R3-AFP) and mortality (SALT and METROTICKET 2.0) in both MC and BMC over a 10-year period (Table 3). This evidence concerns the gene AFP and hepatocellular carcinoma.